» Articles » PMID: 16360021

Induction of Regular Cytolytic T Cell Synapses by Bispecific Single-chain Antibody Constructs on MHC Class I-negative Tumor Cells

Overview
Journal Mol Immunol
Date 2005 Dec 20
PMID 16360021
Citations 179
Authors
Affiliations
Soon will be listed here.
Abstract

Certain bispecific single-chain antibody constructs exhibit an extraordinary potency for polyclonal T cell engagement and target cell lysis. Here we studied the structural basis for this potency, using laser scanning confocal microscopy. Cytolytic human T cell synapses could be triggered either by addition of a specific peptide antigen or an Ep-CAM-/CD3-bispecific T cell engager (BiTE). Both kinds of synapses showed a comparable distribution of all protein markers investigated. Two other BiTEs constructed from different Ep-CAM-specific antibodies gave similar results. BiTEs could also induce lytic synapses between human T cells and a MHC class I-negative, Ep-CAM cDNA-transfected cell line resulting in potent target cell lysis. This shows that certain T cell recognition molecules on target cells are dispensable for synapse formation and BiTE activity, and suggests that BiTE-activated polyclonal T cells may ignore major immune evasion mechanisms of tumor cells in vivo, such as loss of MHC class I expression.

Citing Articles

Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.

Abodunrin F, Olson D, Emehinola O, Bestvina C Ther Adv Med Oncol. 2025; 17:17588359251320280.

PMID: 40012708 PMC: 11863254. DOI: 10.1177/17588359251320280.


The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.

Sun L, Romancik J J Pers Med. 2025; 15(2).

PMID: 39997328 PMC: 11856678. DOI: 10.3390/jpm15020051.


Adoptive T Cell Therapy Targeting MAGE-A4.

Chandora K, Chandora A, Saeed A, Cavalcante L Cancers (Basel). 2025; 17(3).

PMID: 39941782 PMC: 11815873. DOI: 10.3390/cancers17030413.


Bispecific antibody targets and therapies in multiple myeloma.

Rees M, Abdallah N, Yohannan B, Gonsalves W Front Immunol. 2024; 15:1424925.

PMID: 39450163 PMC: 11499143. DOI: 10.3389/fimmu.2024.1424925.


Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab.

Zaninelli S, Panna S, Tettamanti S, Melita G, Doni A, DAutilia F Antibodies (Basel). 2024; 13(3).

PMID: 39311376 PMC: 11417890. DOI: 10.3390/antib13030071.